ストックスクリーナーアプリを入手
2.65
5.16%
0.13
アフターアワーズ：
2.63
-0.02
-0.75%
前日終値:
$2.52
開ける：
$2.53
24時間の取引高:
3.90M
Relative Volume:
0.77
時価総額：
$417.48M
収益：
$101.21M
当期純損益:
$-569.00K
株価収益率:
-132.50
EPS:
-0.02
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
+18.83%
1か月 パフォーマンス:
+306.69%
6か月 パフォーマンス:
+150.00%
1年 パフォーマンス:
+51.43%
1日の値動き範囲:
$2.45
$2.71
1週間の範囲:
$2.10
$2.71
52週間の値動き範囲:
$0.40
$2.71
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.65 | 351.32M | 101.21M | -569.00K | -56.88M | -0.02 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 再開されました | Piper Sandler | Overweight |
| 2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
| 2021-11-15 | 開始されました | BTIG Research | Buy |
| 2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 開始されました | JP Morgan | Overweight |
| 2021-03-23 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-11-26 | 開始されました | Piper Jaffray | Overweight |
| 2018-10-15 | 開始されました | Goldman | Neutral |
| 2018-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2018-06-01 | 開始されました | SunTrust | Buy |
| 2018-01-05 | 開始されました | Citigroup | Buy |
| 2017-09-08 | 開始されました | Wedbush | Outperform |
| 2017-03-27 | 開始されました | H.C. Wainwright | Buy |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
CytomX stock soars to 52-week high, hits $2.66 By Investing.com - Investing.com India
CytomX stock soars to 52-week high, hits $2.66 - Investing.com Australia
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - TradingView
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus
CytomX begins trial of new melanoma treatment with Merck therapy By Investing.com - Investing.com South Africa
CytomX begins trial of new melanoma treatment with Merck therapy - Investing.com Australia
CytomX (CTMX) Advances Phase 1 Study with CX-801 for Metastatic Melanoma | CTMX Stock News - GuruFocus
CytomX Therapeutics Doses First Patient in Phase 1 Study of CX-801 Combined with KEYTRUDA® for Metastatic Melanoma - Nasdaq
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - The Manila Times
Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study - Stock Titan
CytomX upgraded at H.C. Wainwright on trial data for cancer drug - MSN
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
H.C. Wainwright raises CytomX stock to buy, target to $5.00 By Investing.com - Investing.com South Africa
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler - GuruFocus
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus
After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals
CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha
HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX - GuruFocus
H.C. Wainwright raises CytomX stock to buy, target to $5.00 - Investing.com
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus
HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5 - marketscreener.com
CytomX Therapeutics (CTMX) Price Target Doubled Following Promis - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX St - GuruFocus
CytomX Therapeutics (CTMX) Price Target Doubled Following Promising Trial Results | CTMX Stock News - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX Stock News - GuruFocus
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - MSN
Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st
CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets
CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks
CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
CytomX (CTMX) Exceeds Revenue Expectations and Advances CRC Drug Development | CTMX Stock News - GuruFocus
CytomX Therapeutics Reports Q1 2025 Results and Progress - TipRanks
CytomX Therapeutics: Q1 Earnings Snapshot - MySA
CytomX Therapeutics Inc earnings beat by $0.21, revenue topped estimates - Investing.com South Africa
Transcript : CytomX Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Latham & Watkins Advises CytomX Therapeutics on US$100 Million Underwritten Offering of Common Stock - Latham & Watkins LLP
CytomX Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CytomX Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CTMX) - Seeking Alpha
CytomX shares priced at $1.30 in $100 million offering By Investing.com - Investing.com South Africa
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - Benzinga
CytomX Shares Jump After Q1 Beat, 'Positive' Interim Trial Data - marketscreener.com
Earnings call transcript: CytomX Therapeutics Q1 2025 earnings beat expectations - Investing.com
Earnings call transcript: CytomX Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com India
CytomX Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CytomX Therapeutics shares soar on positive cancer drug data By Investing.com - Investing.com Nigeria
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
CytomX Therapeutics shares soar on positive cancer drug data - Investing.com Australia
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):